LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Rare Disease Revenue: $8.8 billion in 2024, up 16%. AstraZeneca PLC (NASDAQ:AZN) reported a strong financial performance in 2024, with total revenue up 21% and core EPS up 19%, indicating robust ...
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results